MEDVi

What MEDVi does

MEDVi is a direct-to-consumer telehealth platform founded in September 2024 by Matthew Gallagher that delivers compounded GLP-1 weight-loss medications (semaglutide and tirzepatide) at price points materially below FDA-approved alternatives — $179 first month / $299 monthly for injectable semaglutide, $249 monthly for oral semaglutide, and $349 monthly for tirzepatide injectable — alongside branded Wegovy/Ozempic/Zepbound offered at $99 membership plus medication cost. The platform operates an online intake and prescription workflow routed to partner physicians (OpenLoop Health, CareGLP affiliated PCs) and fulfillment by licensed compounding pharmacies (Triad Rx, RedRock Pharmacy, Beaker Pharmacy), with services available across a subset of US states.

The company is built on an AI-orchestrated operating model in which more than a dozen AI tools handle coding, marketing content production, customer service chatbots, and business analytics, allowing the platform to run with just two employees and $20,000 in initial capital. The product catalog has expanded beyond weight loss into MEDVi QUAD (a 4-in-1 compounded erectile dysfunction medication), peptides and longevity, women's health, hair restoration, skincare, supplements, and MEDVi Meals (a chef-prepared meal delivery service targeting GLP-1 patients). Customer acquisition is driven primarily by affiliate marketers running paid ads on Meta, with reported use of AI-generated doctor profiles in promotional content.

In its first full year of operation (2025), MEDVi reported $401 million in revenue and $65 million in profit (16.2% net margin) on a base of approximately 250,000 customers, with $1.8 billion projected for 2026 (NYT-verified financials). The company is currently subject to an FDA warning letter issued February 2026 regarding GLP-1 marketing practices, multiple lawsuits alleging AI-generated fake doctor profiles (including a Dr. Anderson likeness suit), class action claims around spam/TCPA violations, and a consumer advocacy group request for FTC investigation — all of which represent material regulatory and reputational risk to the core compounded-GLP-1 revenue stream.

Name

MEDVi

Legal name

MEDVi, LLC

Website

https://medvi.org

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

MEDVi is a direct-to-consumer telehealth platform founded in 2024 that prescribes compounded GLP-1 weight loss medications and erectile dysfunction treatments through partner physicians and compounding pharmacies, generating $401 million in revenue in its first full year.

Ownership category

akta.pro rank

Product category

Direct-to-Consumer Telehealth

NAICS

Offices of Physicians (6211)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro industry

PRIMARYHLALAAAD

Prescription-Based Digital Clinics (Condition-Specific Rx Programs)

Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms

SECONDARYBPAMAHAH

Healthcare On‑Demand Platforms (Telehealth, Home Care, Nursing)

Business & Public Services/Web, Mobile & Digital Platforms/On-Demand, Gig & Local Services Platforms

SECONDARYHLALAIAH

Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing

Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

• Telehealth weight loss
• Compounded GLP-1 medications
• Online ED treatment
• Direct-to-consumer telemedicine
• AI-powered telehealth platform

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Marketing or Sales, Operations, Technology or R&D, Personnel, Infrastructure

Revenue model

1. GLP-1 Weight Loss Program Subscriptions: Monthly subscription model for compounded GLP-1 medications (semaglutide and tirzepatide) with pricing at $179 first month and $299 monthly thereafter. Revenue is recurring subscription-based with auto-renewing memberships.
2. MEDVi QUAD ED Medication: Subscription-based sale of compounded erectile dysfunction medication combining sildenafil, tadalafil, vardenafil, and apomorphine. Priced starting at approximately $114-$119 per month.
3. Wegovy and Brand Medications: Sale of FDA-approved medications including Wegovy at $99 membership plus medication cost. Ozempic and Zepbound also available at higher price points.
4. Affiliate Marketing Revenue: Significant revenue driven by affiliate marketers who promote products and earn commissions on referred customers.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

MEDVi operates a direct-to-consumer telehealth platform that evaluates patients online and dispenses compounded GLP-1 weight-loss medications (semaglutide and tirzepatide, oral and injectable), the proprietary MEDVi QUAD 4-in-1 erectile dysfunction therapy, peptide and longevity treatments, women's health programs, supplements, and MEDVi Meals portion-controlled nutrition. Each program bundles physician consultation, prescription, ongoing coaching, 24/7 support, and home delivery on a recurring monthly subscription.

Differentiator

Problem solved

Functional benefit

Brands

• MEDVi Meals: Chef-made, portion-controlled meal delivery service designed to support GLP-1 weight loss journey
• MEDVi QUAD

Products and services

• GLP-1 Weight Loss Program (Compounded Semaglutide and Tirzepatide) Doctor-supervised, subscription-based weight-loss program delivered through the MEDVi telehealth platform; includes online intake, physician evaluation, prescription of compounded GLP-1 medication (semaglutide or tirzepatide, injectable or oral) shipped to the patient's door, 1:1 physician guidance, free dietician visits, care coaching, and 24/7 support. Targeted at US adults without insurance coverage for FDA-approved weight-loss drugs.
• MEDVi QUAD Erectile Dysfunction Treatment Subscription-based, compounded erectile dysfunction medication combining sildenafil, tadalafil, vardenafil, and apomorphine into a single sublingual rapid-absorb dose, with online physician consultation, free rush shipping, and 24/7 support; positioned as a comprehensive alternative to single-ingredient PDE5 inhibitors for US men with ED.
• MEDVi Meals

Quantifiable outcome

• 18% average body weight loss for patients on GLP-1 treatment over first 6 months
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• OpenLoop HealthcoreStrategic or Co-development PartnerNetwork of US-licensed doctors providing clinical services for MEDVi patients. OpenLoop Health adheres to rigorous medical protocols designed for patient safety and conducts telehealth consultations and determines prescription eligibility.
• CareGLP Affiliated P.C.scoreStrategic or Co-development PartnerAffiliated professional corporations providing medical treatment services through the MEDVi platform. These entities employ or contract with licensed healthcare providers.
• Triad RxcoreOthersPartner pharmacy dispensing compounded medications. Located at 26258 Pollard Rd, Daphne, AL 36526. One of multiple certified pharmacies in MEDVi's network.
• RedRock PharmacycoreOthersPartner pharmacy fulfilling prescriptions. Located at 1240 E 100 S #220, St. George, UT 84790. Certified pharmacy providing medication preparation and shipping.
• Beaker Pharmacy & CompoundingcoreOthersCompounding pharmacy partner preparing customized medications. Located at 7810 Eldorado Pkwy STE 200, McKinney, TX 75072.
• Affiliate MarketerscoreGTM or Marketing PartnerThird-party affiliate marketers who run paid advertisements promoting MEDVi products. These affiliates have been the subject of controversy for using AI-generated fake doctor profiles in advertisements.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ro: Ro operates a DTC telehealth platform that includes Ro Body (GLP-1 weight loss) and Roman (men's health/ED). Directly comparable to MEDVi's core weight-loss and men's health subscription offerings.
• Hims & Hers Health: Hims & Hers is a publicly-traded DTC telehealth platform offering GLP-1 weight-loss programs along with men's and women's health. Direct competitor to MEDVi across weight loss, ED, and broader telehealth subscription verticals.
• Sesame: Sesame is a DTC telehealth marketplace offering weight-loss consultations and prescriptions at transparent cash-pay pricing. Comparable business model of online intake, physician review, and direct medication delivery.
• Mochi Health: Mochi Health is a telehealth platform offering GLP-1 weight-loss programs with physician visits and compounded medication fulfillment. Targets the same price-sensitive consumer cohort as MEDVi.
• LifeMD: LifeMD is a telemedicine company with a direct-to-consumer GLP-1 weight-loss program. Competes head-to-head with MEDVi on compounded GLP-1 telehealth subscriptions.
• Henry Meds: Henry Meds is a DTC telehealth provider of compounded GLP-1 weight-loss medications with a similar cost-leadership, subscription-based model. Closest analog to MEDVi in the compounded-GLP-1 telehealth niche.
• Noom Med: Noom Med is the prescription/telehealth arm of Noom, providing GLP-1 medications alongside behavior-change coaching. Directly comparable to MEDVi's combination of physician-guided GLP-1 therapy and ongoing support.

Broad incumbents

• WeightWatchers (WW): WeightWatchers has expanded into compounded GLP-1 telehealth via its WeightWatchers Clinic program. A larger incumbent with established consumer brand awareness now competing in MEDVi's core GLP-1 telehealth category.

Emerging players

• Lemonaid Health: Lemonaid Health (now part of 23andMe) is an online clinic offering prescription treatments including weight management. Comparable online intake, physician-prescribing, and home-delivery model.
• Found (Found Health): Found is a DTC telehealth platform combining physician-supervised weight management with GLP-1 access. Overlaps MEDVi's weight-loss telehealth offering with a more behavior-coaching-led approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEDVi